ライフサイエンスコーパス: Kaplan-Meier analysis

1 y end point was to compare overall survival (Kaplan-Meier analysis).

2 were 6.5% and 6.7%, respectively (unadjusted Kaplan-Meier analysis).

3 84% for pre-LT and 93% for post-LT patients (Kaplan-Meier analysis).

4 corneal thickness (CCT), and graft survival (Kaplan-Meier analysis).

5 d 71% at 1, 3, and 5 years, respectively, by Kaplan Meier analysis.

6 Survival was analyzed by Kaplan-Meier analysis.

7 al of bladder cancer patients as revealed by Kaplan-Meier analysis.

8 ation of reduced recurrence-free survival by Kaplan-Meier analysis.

9 999 copies/mL) for 6, 9, or 12 months, using Kaplan-Meier analysis.

10 tive risk (lambda) and cumulative risk using Kaplan-Meier analysis.

11 number of photographs taken was evaluated by Kaplan-Meier analysis.

12 stable microsatellites P = .0415), based on Kaplan-Meier analysis.

13 rates divided by incidence, as estimated by Kaplan-Meier analysis.

14 tional hazards regression model analysis and Kaplan-Meier analysis.

15 rvival (PFS) and overall survival (OS) using Kaplan-Meier analysis.

16 ion-free survival and overall survival using Kaplan-Meier analysis.

17 Survival was assessed using Kaplan-Meier analysis.

18 us immunosuppressant use was estimated using Kaplan-Meier analysis.

19 ar cumulative percentage of MAE was 12.5% by Kaplan-Meier analysis.

20 cause-specific survival (CSS), P = 0.012] by Kaplan-Meier analysis.

21 al hazards modeling and were evaluated using Kaplan-Meier analysis.

22 tuarial overall survival was calculated with Kaplan-Meier analysis.

23 Long-term survival was evaluated by Kaplan-Meier analysis.

24 m the first TACE session was calculated with Kaplan-Meier analysis.

25 cumulative incidence of PD was calculated by Kaplan-Meier analysis.

26 tients was assessed using Cox regression and Kaplan-Meier analysis.

27 dney transplants at the same center by using Kaplan-Meier analysis.

28 tients was assessed using Cox regression and Kaplan-Meier analysis.

29 Survival was determined by Kaplan-Meier analysis.

30 atus, and time to recurrence on the basis of Kaplan-Meier analysis.

31 elopment of metastases was analyzed by using Kaplan-Meier analysis.

32 n 1 year of transplantation were assessed by Kaplan-Meier analysis.

33 ranslocation in human PNI was analyzed using Kaplan-Meier analysis.

34 Survival was determined by Kaplan-Meier analysis.

35 and HIV-1-free survival were assessed using Kaplan-Meier analysis.

36 g-donor KTA or with a LKTx was obtained from Kaplan-Meier analysis.

37 ecreased patient and graft survival rates by Kaplan-Meier analysis.

38 which was significant in both chi-square and Kaplan-Meier analysis.

39 (+/- distant metastasis) were calculated by Kaplan-Meier analysis.

40 n rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis.

41 ative risk of treatment failure by day 28 by Kaplan-Meier analysis.

42 associated genetic variants were assessed by Kaplan-Meier analysis.

43 he recurrence-free curve was estimated using Kaplan-Meier analysis.

44 d probability of rebound and resistance with Kaplan-Meier analysis.

45 splantation graft survival was assessed with Kaplan-Meier analysis.

46 oth univariate and multivariate analysis and Kaplan-Meier analysis.

47 A, NRP-1, FOXO 3a and MelCAM were studied by Kaplan-Meier analysis.

48 Device longevity was estimated using Kaplan-Meier analysis.

49 The patency was evaluated by Kaplan-Meier analysis.

50 th graft survival was also explored by using Kaplan-Meier analysis.

51 ression analysis (37.4%) or the results of a Kaplan-Meier analysis (10.5%).

52 e who did not have angiography, according to Kaplan-Meier analysis (281/3085 [12.8%] vs 480/4158 [16.

53 By Kaplan-Meier analysis, 5-year survival was 35.7% (95% co

54 By using a Kaplan-Meier analysis, a person's cumulative probability

55 median follow-up of 5.2 (3.6, 6.9) years on Kaplan-Meier analysis, a significant nonlinear associati

56 Kaplan-Meier analysis also showed that freedom from 50%

57 In a Kaplan-Meier analysis, amyloid positive subjects with mi

58 overall survival discrimination, with use of Kaplan Meier analysis and a univariate Cox proportional

59 nt recipients 61 years of age or older using Kaplan- Meier analysis and Cox proportional hazard model

60 ters and survival time was assessed by using Kaplan-Meier analysis and a Cox proportional hazards mod

61 to cancer in the two groups was compared by Kaplan-Meier analysis and a Cox proportional-hazards mod

62 ed time to progression was assessed by using Kaplan-Meier analysis and a Cox regression model.

63 se Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covar

64 sed mortality within 90 days of operation by Kaplan-Meier analysis and assessed the role of patient a

65 We analysed events by Kaplan-Meier analysis and compared groups with a Cox pro

66 ated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysi

67 tality were analyzed by NYHA IV status using Kaplan-Meier analysis and Cox proportional hazard models

68 s and survival outcomes were investigated by Kaplan-Meier analysis and Cox proportional hazard models

69 We used Kaplan-Meier analysis and Cox proportional hazard models

70 Recurrence and survival were analyzed using Kaplan-Meier analysis and Cox proportional hazards model

71 Kaplan-Meier analysis and Cox proportional hazards regre

72 Survival was analyzed using Kaplan-Meier analysis and Cox proportional hazards regre

73 Kaplan-Meier analysis and Cox proportional hazards regre

74 Survival analysis was conducted using Kaplan-Meier analysis and Cox regression analysis.

75 Kaplan-Meier analysis and Cox regression models were use

76 idence of clinical outcome was determined by Kaplan-Meier analysis and Cox regression was used to eva

77 Kaplan-Meier analysis and Cox regression were used to ev

78 Kaplan-Meier analysis and Cox regression were used to se

79 Survival analysis was performed with Kaplan-Meier analysis and Cox regression.

80 Kaplan-Meier analysis and Fisher's exact test were used

81 Kaplan-Meier analysis and global nonlinear regression re

82 Kaplan-Meier analysis and hazard ratios were calculated

83 ere complete success rates at 24 months with Kaplan-Meier analysis and incidence of adverse events.

84 Median ages at LoA were compared by Kaplan-Meier analysis and log-rank test.

85 By Kaplan-Meier analysis and log-rank testing, progression-

86 Kaplan-Meier analysis and multivariable Cox proportional

87 Univariate Kaplan-Meier analysis and multivariate Cox proportional

88 Patient survival was determined using Kaplan-Meier analysis and predictors of mortality were i

89 Survival was evaluated by using Kaplan-Meier analysis and was compared by using Cox prop

90 HCC incidence was determined by Kaplan-Meier analysis, and baseline factors associated w

91 Bi- and multivariable logistic regression, Kaplan-Meier analysis, and Cox proportional hazards mode

92 Disease risk was assessed with Kaplan-Meier analysis, and epidemiologic variables were

93 tical methods included analysis of variance, Kaplan-Meier analysis, and Mantel-Cox proportional hazar

94 mption of continuous smoking was assessed by Kaplan-Meier analysis, and risk differences between grou

95 Primary patency by Kaplan-Meier analysis at 12 months (360 days) was 86.3%.

96 In the Kaplan-Meier analysis at 24 weeks, the rate of death wit

97 s azathioprine was significantly improved by Kaplan-Meier analysis at 4 years (85.61% v. 81.9%).

98 success of second glaucoma drainage devices (Kaplan-Meier analysis) at 1 year, 2 years, and 3 years w

99 The Kaplan-Meier analysis based on our patients cohort and t

100 The Kaplan-Meier analysis confirmed this result, with a 2-y

101 In univariate Kaplan-Meier analysis, counts of total (p = 0.010), clas

102 respect to HNSCC staging were compared using Kaplan-Meier analysis, Cox proportional hazards regressi

103 Kaplan-Meier analysis demonstrated a 5-year OS of 81% in

104 Kaplan-Meier analysis demonstrated a cumulative mortalit

105 Kaplan-Meier analysis demonstrated a dose-dependent decr

106 Kaplan-Meier analysis demonstrated a lower risk for graf

107 Kaplan-Meier analysis demonstrated a significant associa

108 Kaplan-Meier analysis demonstrated an 88.5% freedom from

109 Kaplan-Meier analysis demonstrated an increased risk of

110 Kaplan-Meier analysis demonstrated complete success rate

111 Kaplan-Meier analysis demonstrated few vision losses dur

112 Kaplan-Meier analysis demonstrated significant differenc

113 However, Kaplan-Meier analysis demonstrated significantly diminis

114 Kaplan-Meier analysis demonstrated significantly greater

115 Kaplan-Meier analysis demonstrated that a PFR of <1.4 wa

116 Kaplan-Meier analysis demonstrated that a stem cell-like

117 Kaplan-Meier analysis demonstrated that ADT users 70 yea

118 Kaplan-Meier analysis demonstrated that patients in the

119 Kaplan-Meier analysis demonstrated that patients with PV

120 Kaplan-Meier analysis demonstrated that patterns of alig

121 Kaplan-Meier analysis demonstrated that recurrence predi

122 A Kaplan-Meier analysis demonstrated that the 1.6 mA-min d

123 Kaplan-Meier analysis demonstrated that the absence of b

124 Kaplan-Meier analysis demonstrated that the disease-free

125 Furthermore, the results obtained via Kaplan-Meier analysis demonstrated the potential of radi

126 A Kaplan-Meier analysis evaluated the probability and its

127 By Kaplan-Meier analysis, event-free survival was significa

128 tumor location demonstrated superior BCSS on Kaplan-Meier analysis for both local stage (node-negativ

129 Kaplan-Meier analysis for cumulative patient survival de

130 We applied Kaplan-Meier analysis for survival curves and mortality

131 By unadjusted Kaplan-Meier analysis for the composite end point of dea

132 The Kaplan-Meier analysis for time to first patency loss was

133 Kaplan-Meier analysis found a 9.7-month difference in me

134 By Kaplan-Meier analysis, freedom from AAA rupture was 97.6

135 By Kaplan-Meier analysis, freedom from reintervention was 6

136 By Kaplan-Meier analysis, HCC incidence was higher, but not

137 In a Kaplan-Meier analysis, high baseline ADCC (>median) was

138 Successful trabeculectomies, determined by Kaplan-Meier analysis, in which patients have intraocula

139 Kaplan-Meier analysis, including all patients with any s

140 By Kaplan-Meier analysis, inclusion of currently unaffected

141 Kaplan-Meier analysis indicated a shorter survival time

142 Additional Kaplan-Meier analysis indicated that patients on HAART h

143 Kaplan-Meier analysis indicated that patients with CED h

144 Kaplan-Meier analysis indicates that the current AJCC sy

145 as more likely in group 1 than in group 2 in Kaplan-Meier analysis (Log Rank P=0.04).

146 gher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univa

147 iac risk factors and CMR were significant in Kaplan-Meier analysis (log-rank test, p = 0.0006 and p <

148 icantly with poor survival prognosis using a Kaplan-Meier analysis (log-rank test, P=5 x 10(-4)), sug

149 Kaplan-Meier analysis, log-rank tests, Fine and Gray com

150 By Kaplan-Meier analysis, median freedom from conduit surge

151 ariate adjusted outcomes were assessed using Kaplan-Meier analysis, multivariate cox regression, mult

152 Kaplan-Meier analysis (n=426) demonstrated a cumulative

153 A Kaplan-Meier analysis of 45 patients revealed that highe

154 Three prediction methods were compared, Kaplan-Meier analysis of all possible subsets, recursive

155 Kaplan-Meier analysis of all the 294 adenocarcinoma nodu

156 Kaplan-Meier analysis of beta6 expression in 488 colorec

157 Kaplan-Meier analysis of both types of tumors showed tha

158 Kaplan-Meier analysis of data from 3455 patients with br

159 ere randomized into eight treatment arms for Kaplan-Meier analysis of defined survival end-point (3.0

160 Kaplan-Meier analysis of DFS and OS was performed and in

161 Kaplan-Meier analysis of disease-free survival and overa

162 Kaplan-Meier analysis of graft and patient survival and

163 Kaplan-Meier analysis of graft and patient survival foun

164 The aggregated Kaplan-Meier analysis of immunotherapy trials vs chemoth

165 Kaplan-Meier analysis of metastasis-free survival and ov

166 Kaplan-Meier analysis of node-negative and node-positive

167 Kaplan-Meier analysis of our population indicated a 1-y

168 Kaplan-Meier analysis of overall survival (OS), progress

169 Descriptive statistics and Kaplan-Meier analysis of overall survival are reported.

170 Kaplan-Meier analysis of rates of radiation complication

171 A Kaplan-Meier analysis of recurrence-free survival showed

172 FINDINGS: Kaplan-Meier analysis of the Kaiser validation cohort sh

173 up vs 43.3% (565/1304) in the placebo group, Kaplan-Meier analysis of time to death by 1 year, P = .7

174 Kaplan-Meier analysis of time to first reversal showed a

175 By Kaplan-Meier analysis, OS, PFS, and LPFS were lower in p

176 In Kaplan-Meier analysis over a 5-year follow-up period, su

177 By Kaplan-Meier analysis, overall survival was significantl

178 development of metastases of primary tumors (Kaplan-Meier analysis P = 0.001).

179 ssociated with survival from presentation in Kaplan-Meier analysis (p < 0.01), and loss of 1p36 and 1

180 higher incidence of cardiovascular events by Kaplan-Meier analysis (p = 0.033, log-rank test).

181 eved a 49% increase in tumor growth delay by Kaplan-Meier analysis (P = 0.0367; n = 6).

182 antly lower overall mortality, determined by Kaplan-Meier analysis (P=.0047), univariate Cox regressi

183 By Kaplan-Meier analysis, patients whose pancreatic cancer

184 Using Kaplan-Meier analysis, patients with lower DC counts (<

185 By Kaplan-Meier analysis, patients with MOLLI-ECV >/= the m

186 Survival (Kaplan-Meier) analysis results suggest that the expressi

187 Kaplan-Meier analysis revealed a comparable survival pro

188 Kaplan-Meier analysis revealed a stepwise increase in mo

189 Kaplan-Meier analysis revealed a tendency of AR patients

190 Kaplan-Meier analysis revealed event-free survival for s

191 Kaplan-Meier analysis revealed no significant difference

192 Kaplan-Meier analysis revealed significant mortality bet

193 Kaplan-Meier analysis revealed similarly low cardiac eve

194 Interestingly, Kaplan-Meier analysis revealed that a combined promoter

195 nipulation and no AI at the time of implant, Kaplan-Meier analysis revealed that freedom from greater

196 Kaplan-Meier analysis revealed that mortality and cardio

197 Kaplan-Meier analysis revealed that patients on hemodial

198 Kaplan-Meier analysis revealed that performance of AVR (

199 Kaplan-Meier analysis revealed that survival through day

200 A Kaplan-Meier analysis revealed that the rates of primary

201 Kaplan-Meier analysis revealed the tendency of sleep apn

202 In Kaplan-Meier analysis, serum phosphate concentration was

203 Kaplan-Meier analysis showed a cumulative incidence of m

204 Kaplan-Meier analysis showed a freedom from recurrent em

205 Kaplan-Meier analysis showed a mean time of recurrence o

206 Kaplan-Meier analysis showed a significant improvement i

207 Kaplan-Meier analysis showed a significantly lower event

208 Kaplan-Meier analysis showed clear stratification of hig

209 Twelve months after PIER, Kaplan-Meier analysis showed limb salvage rate was 66%,

210 Findings from the Kaplan-Meier analysis showed no association between the

211 Kaplan-Meier analysis showed no differences in the incid

212 Kaplan-Meier analysis showed no significant differences

213 Kaplan-Meier analysis showed primary iliofemoral venous

214 Kaplan-Meier analysis showed significantly better surviv

215 Kaplan-Meier analysis showed similar cancer risks betwee

216 Kaplan-Meier analysis showed similar cancer risks betwee

217 Kaplan-Meier analysis showed statistically significant d

218 Kaplan-Meier analysis showed survival was 78% at 5 years

219 After 5 years, Kaplan-Meier analysis showed sustained complete remissio

220 Kaplan-Meier analysis showed that DM patients had a redu

221 Kaplan-Meier analysis showed that dysplasia remained era

222 Kaplan-Meier analysis showed that if a high-quality phot

223 In brain cancer patients, Kaplan-Meier analysis showed that image-derived referenc

224 Kaplan-Meier analysis showed that levels of interleukin-

225 Kaplan-Meier analysis showed that one- and two-year graf

226 In ER positive cases, Kaplan-Meier analysis showed that patients with lower mi

227 Kaplan-Meier analysis showed that the 1-, 5-, and 10-yea

228 Kaplan-Meier analysis showed that the complete success r

229 A Kaplan-Meier analysis showed that the probability of dev

230 Kaplan-Meier analysis showed that the vaccine group was

231 Kaplan-Meier analysis showed worse survival for patients

232 The Kaplan-Meier analysis shows a trend toward greater freed

233 Kaplan-Meier analysis suggested that neuromonitoring was

234 Kaplan-Meier analysis suggests there is at least an addi

235 On Kaplan-Meier analysis, the 3-year freedom from ipsilater

236 On Kaplan-Meier analysis, the median survival in the entire

237 With Kaplan-Meier analysis, the risk of death increased signi

238 According to a Kaplan-Meier analysis, the time to healing was shorter f

239 On Kaplan-Meier analysis there were no differences in short

240 By Kaplan-Meier analysis, there was no difference in freedo

241 Using unadjusted and adjusted Cox models and Kaplan-Meier analysis, there was no significant differen

242 In Kaplan-Meier analysis, there was significant variability

243 We used Kaplan-Meier analysis to assess disease-specific surviva

244 learance kinetics, measured every 6 h, and a Kaplan-Meier analysis to compare parasite clearance kine

245 We used Kaplan-Meier analysis to evaluate the number of cases of

246 We also conducted Kaplan-Meier analysis to include currently unaffected mu

247 In a Kaplan-Meier analysis, two-year and five-year rates of c

248 The associations were further delineated by Kaplan-Meier analysis using publicly available mRNA expr

249 By Kaplan-Meier analysis, VA less than 20/200 at 3 years wa

250 One-year graft survival by Kaplan Meier analysis was 81% and 84% in the AHR and ACR

251 The 5-year graft survival by Kaplan Meier analysis was better in SA group than in MA

252 Estimated mean survival time in the Kaplan-Meier analysis was 147 months (95% confidence int

253 Median renal survival from diagnosis by Kaplan-Meier analysis was 5.4 years, and median estimate

254 The estimated cumulative CO rates using Kaplan-Meier analysis was 68%.

255 Survival by Kaplan-Meier analysis was 77% at 1 year, 62% at 3 years,

256 Five-year disease-free survival on Kaplan-Meier analysis was 82%, and 5-year overall surviv

257 Survival by Kaplan-Meier analysis was 94% (SE 0.01), 91% (0.02), and

258 Median overall survival by Kaplan-Meier analysis was compared between groups using

259 Patient survival by Kaplan-Meier analysis was higher in hepatitis C-positive

260 Kaplan-Meier analysis was performed for censored graft s

261 Kaplan-Meier analysis was performed for PTLD-free surviv

262 Kaplan-Meier analysis was performed for time to developm

263 Kaplan-Meier analysis was performed to compare AZA vs. M

264 Kaplan-Meier analysis was performed to compare time to e

265 Kaplan-Meier analysis was performed to determine the rel

266 Kaplan-Meier analysis was performed to determine the tim

267 Kaplan-Meier analysis was performed to estimate the cumu

268 A Kaplan-Meier analysis was performed to estimate time to

269 Kaplan-Meier analysis was performed to evaluate graft su

270 tory abilities of inflammation-based scores; Kaplan-Meier analysis was performed to plot the survival

271 Kaplan-Meier analysis was performed using Criteria A (po

272 Gene-expression based Kaplan-Meier analysis was performed using The Cancer Gen

273 Descriptive statistics and Kaplan-Meier analysis was performed.

274 as in patients with limited life expectancy, Kaplan-Meier analysis was repeated including only patien

275 Kaplan-Meier analysis was then performed on overall graf

276 Kaplan-Meier analysis was used to assess freedom from ne

277 mplications and of need for reoperation, and Kaplan-Meier analysis was used to assess graft survival

278 Kaplan-Meier analysis was used to assess ocular outcome

279 Kaplan-Meier analysis was used to assess the time betwee

280 Kaplan-Meier analysis was used to compute progression-fr

281 Kaplan-Meier analysis was used to determine median time

282 Kaplan-Meier analysis was used to estimate freedom from

283 Kaplan-Meier analysis was used to estimate the cumulativ

284 Kaplan-Meier analysis was used to estimate the risk of r

285 Kaplan-Meier analysis was used to estimate the time to d

286 Kaplan-Meier analysis was used to examine rates of recip

287 Kaplan-Meier analysis was used to obtain survival rates.

288 At 1 year, the rate of death from any cause (Kaplan-Meier analysis) was 30.7% with TAVI, as compared

289 l success at the last follow-up according to Kaplan-Meier analysis were 100% and 94.4% in bevacizumab

290 Five-year patient and graft survivals by Kaplan-Meier analysis were significantly lower for type

291 Univariate, multivariate, and Kaplan-Meier analysis were used as appropriate.

292 Cox multivariable regression and Kaplan-Meier analysis were used to identify factors asso

293 [CI], 0.71 to 1.15; P=0.41) and at 2 years (Kaplan-Meier analysis) were 33.9% in the TAVR group and

294 he 1-, 12-, and 24-month mortality rates (by Kaplan-Meier analysis) were 4.5%, 15.8%, and 15.8%, resp

295 CD20+ cells/hpf had worse graft survival in Kaplan-Meier analysis with a hazard ratio 4.56 (CI 1.07-

296 Kaplan-Meier analysis with log-rank test was used to det

297 Overall survival (OS) was compared using Kaplan-Meier analysis with log-rank tests and multivaria

298 Overall survival was compared using Kaplan-Meier analysis with log-rank tests, multivariable

299 Univariate Cox regression and Kaplan-Meier analysis with respect to overall survival (

300 With median follow up of 29.1 months, Kaplan-Meier analysis with the log-rank test demonstrate